News AZ's Lynparza impresses with new ovarian cancer data UK firm lays down the gauntlet in the PARP inhibitor battle.
News Early Clovis approval notches up competition in ovarian canc... Clovis' Rubraca will compete against AstraZeneca rival.
News Electrical patch device shows promise against ovarian cancer Novocure's Optune device shown to be safe and tolerable in recurrent ovarian cancer.
News Clovis takes stock as rival Tesaro shines Oncology firm could make acquisition if ovarian cancer drug approved.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
